Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations

Bibliographic Details
Title: Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations
Authors: Lucia Mora-Jimenez, Miguel Valencia, Rocio Sanchez-Carpintero, Jan Tønnesen, Saja Fadila, Moran Rubinstein, Manuela Gonzalez-Aparicio, Maria Bunuales, Eva Fernandez-Pierola, Maria Jesus Nicolas, Elena Puerta, Cristina Miguelez, Paula Gimenez Minguez, Sara Lumbreras, Gloria Gonzalez-Aseguinolaza, Ana Ricobaraza, Ruben Hernandez-Alcoceba
Source: Molecular Therapy: Nucleic Acids, Vol 25, Iss , Pp 585-602 (2021)
Publisher Information: Elsevier, 2021.
Publication Year: 2021
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: SCN1A, Nav1.1., Dravet syndrome, epilepsy, encephalopathy, adenovirus, Therapeutics. Pharmacology, RM1-950
More Details: Dravet syndrome is a genetic encephalopathy characterized by severe epilepsy combined with motor, cognitive, and behavioral abnormalities. Current antiepileptic drugs achieve only partial control of seizures and provide little benefit on the patient’s neurological development. In >80% of cases, the disease is caused by haploinsufficiency of the SCN1A gene, which encodes the alpha subunit of the Nav1.1 voltage-gated sodium channel. Novel therapies aim to restore SCN1A expression in order to address all disease manifestations. We provide evidence that a high-capacity adenoviral vector harboring the 6-kb SCN1A cDNA is feasible and able to express functional Nav1.1 in neurons. In vivo, the best biodistribution was observed after intracerebral injection in basal ganglia, cerebellum, and prefrontal cortex. SCN1A A1783V knockin mice received the vector at 5 weeks of age, when most neurological alterations were present. Animals were protected from sudden death, and the epileptic phenotype was attenuated. Improvement of motor performance and interaction with the environment was observed. In contrast, hyperactivity persisted, and the impact on cognitive tests was variable (success in novel object recognition and failure in Morris water maze tests). These results provide proof of concept for gene supplementation in Dravet syndrome and indicate new directions for improvement.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2162-2531
Relation: http://www.sciencedirect.com/science/article/pii/S2162253121001979; https://doaj.org/toc/2162-2531
DOI: 10.1016/j.omtn.2021.08.003
Access URL: https://doaj.org/article/d8a21f6b96294c4686222a2f4ad8317e
Accession Number: edsdoj.8a21f6b96294c4686222a2f4ad8317e
Database: Directory of Open Access Journals
More Details
ISSN:21622531
DOI:10.1016/j.omtn.2021.08.003
Published in:Molecular Therapy: Nucleic Acids
Language:English